Associations Between the Big Five Personality Traits and the Non-Medical Use of Prescription Drugs for Cognitive Enhancement

Sattler S, Schunck R (2016)
Frontiers in Psychology 6: 1971.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA 1.07 MB
Abstract / Bemerkung
While the number of studies of the non-medical use of prescription drugs to augment cognitive functions is growing steadily, psychological factors that can potentially help explain variance in such pharmaceutical cognitive enhancement (CE) behavior are often neglected in research. This study investigates the association between the Big Five personality traits and a retrospective (prior CE-drug use) as well as a prospective (willingness to use CE drugs) measure of taking prescription drugs with the purpose of augmenting one's cognitive functions (e.g., concentration, memory, or vigilance) without medical necessity. We use data from a large representative survey of German employees (N = 6454, response rate = 29.8%). The Five Factor Model (FFM) of Personality was measured with a short version of the Big Five Personality Traits Inventory (BFI-S), which includes: openness to experience, conscientiousness, extraversion, agreeableness, and neuroticism. Together with this, demographic variables such as gender, age, education, and income were used as potential confounders in multiple logistic regression models. Our results show a 2.96% lifetime prevalence of CE-drug use and a 10.45% willingness to (re)use such drugs in the future. We found that less conscientious and more neurotic respondents have a higher probability of prior CE-drug use and a greater willingness to use CE drugs in the future. No significant effects were found for openness, extraversion, or agreeableness. Prior CE-drug use was strongly associated with a greater willingness to take such drugs in the future. This study shows that specific personality traits are not only associated with prior enhancement behavior, but also affect the willingness to (re)use such drugs. It helps increase understanding of the risk factors of CE-drug use, which is a health-related behavior that can entail severe side-effects for consumers. The knowledge gathered can thus help improve interventions aimed at minimizing health problems.
Erscheinungsjahr
2016
Zeitschriftentitel
Frontiers in Psychology
Band
6
Art.-Nr.
1971
ISSN
1664-1078
Finanzierungs-Informationen
Open-Access-Publikationskosten wurden durch die Deutsche Forschungsgemeinschaft und die Universität Bielefeld gefördert.
Page URI
https://pub.uni-bielefeld.de/record/2900270

Zitieren

Sattler S, Schunck R. Associations Between the Big Five Personality Traits and the Non-Medical Use of Prescription Drugs for Cognitive Enhancement. Frontiers in Psychology. 2016;6: 1971.
Sattler, S., & Schunck, R. (2016). Associations Between the Big Five Personality Traits and the Non-Medical Use of Prescription Drugs for Cognitive Enhancement. Frontiers in Psychology, 6, 1971. https://doi.org/10.3389/fpsyg.2015.01971
Sattler, Sebastian, and Schunck, Reinhard. 2016. “Associations Between the Big Five Personality Traits and the Non-Medical Use of Prescription Drugs for Cognitive Enhancement”. Frontiers in Psychology 6: 1971.
Sattler, S., and Schunck, R. (2016). Associations Between the Big Five Personality Traits and the Non-Medical Use of Prescription Drugs for Cognitive Enhancement. Frontiers in Psychology 6:1971.
Sattler, S., & Schunck, R., 2016. Associations Between the Big Five Personality Traits and the Non-Medical Use of Prescription Drugs for Cognitive Enhancement. Frontiers in Psychology, 6: 1971.
S. Sattler and R. Schunck, “Associations Between the Big Five Personality Traits and the Non-Medical Use of Prescription Drugs for Cognitive Enhancement”, Frontiers in Psychology, vol. 6, 2016, : 1971.
Sattler, S., Schunck, R.: Associations Between the Big Five Personality Traits and the Non-Medical Use of Prescription Drugs for Cognitive Enhancement. Frontiers in Psychology. 6, : 1971 (2016).
Sattler, Sebastian, and Schunck, Reinhard. “Associations Between the Big Five Personality Traits and the Non-Medical Use of Prescription Drugs for Cognitive Enhancement”. Frontiers in Psychology 6 (2016): 1971.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2019-09-06T09:18:34Z
MD5 Prüfsumme
fb94a9651673112228f2aa76b746cb8c


112 References

Daten bereitgestellt von Europe PubMed Central.

Personality correlates of risky health outcomes: findings from a large Internet study
Atherton O., Robins R., Rentfrow P., Lamb M.., 2014
Multiple imputation by chained equations: what is it and how does it work?
Azur MJ, Stuart EA, Frangakis C, Leaf PJ., Int J Methods Psychiatr Res 20(1), 2011
PMID: 21499542
Personality stability and adolescent substance use behaviors.
Bates ME, Pandina RJ., Alcohol. Clin. Exp. Res. 15(3), 1991
PMID: 1877731
Predicting dishonest actions using the theory of planned behavior
Beck L., Ajzen I.., 1991
Australian university students' attitudes towards the acceptability and regulation of pharmaceuticals to improve academic performance
Bell S., Partridge B., Lucke J., Hall W.., 2013
WeLL – unique linked employer-employee data on further training in Germany
Bender S., Fertig M., Görlitz K., Huber M., Schmucker A.., 2009
The five factor model of personality and the non-medical use of prescription drugs: Associations in a young adult sample
Benotsch E., Jeffers A., Snipes D., Martin A., Koester S.., 2013
NEO-PI-R. NEO-Persönlichkeitsinventar nach Costa und McCrae. Revidierte Fassung von Fritz Ostendorf und Alois Angleitner
Berth H., Goldschmidt S.., 2004
Associations between major domains of personality and health behavior.
Booth-Kewley S, Vickers RR Jr., J Pers 62(3), 1994
PMID: 7965560
Cognitive enhancement: methods, ethics, regulatory challenges.
Bostrom N, Sandberg A., Sci Eng Ethics 15(3), 2009
PMID: 19543814

Butcher J.., 2010
Personality development across the life course
Caspi A.., 1998
Personality development: stability and change.
Caspi A, Roberts BW, Shiner RL., Annu Rev Psychol 56(), 2005
PMID: 15709943
Use of cognitive enhancement medication among northern Italian university students.
Castaldi S, Gelatti U, Orizio G, Hartung U, Moreno-Londono AM, Nobile M, Schulz PJ., J Addict Med 6(2), 2012
PMID: 22456492
The sixteen personality factor questionnaire (16PF)
Cattell H., Mead A.., 2008
Cognitive biases can affect moral intuitions about cognitive enhancement.
Caviola L, Mannino A, Savulescu J, Faulmuller N., Front Syst Neurosci 8(), 2014
PMID: 25360088
Long-term effects of a personality-targeted intervention to reduce alcohol use in adolescents.
Conrod PJ, Castellanos-Ryan N, Mackie C., J Consult Clin Psychol 79(3), 2011
PMID: 21500886

AUTHOR UNKNOWN, 2009
Persönlichkeitsmerkmale im Sozio-oekonomischen Panel (SOEP)-Konzept, Umsetzung und empirische Eigenschaften
Dehne M., Schupp J.., 2007
The SFB882-B3 linked employer-employee panel survey (LEEP-B3)
Diewald M., Schunck R., Abendroth A.-K., Melzer S., Pausch S., Jacobebbinghaus P.., 2014
Non-pharmacological cognitive enhancement.
Dresler M, Sandberg A, Ohla K, Bublitz C, Trenado C, Mroczko-Wasowicz A, Kuhn S, Repantis D., Neuropharmacology 64(), 2012
PMID: 22828638
Cognitive enhancement and academic misconduct: a study exploring their frequency and relationship
Dubljević V., Sattler S., Racine É.., 2014
Addiction, personality and motivation
Eysenck H.., 1999
Neurocognitive enhancement: what can we do and what should we do?
Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel E, King P, Parens E, Sahakian B, Wolpe PR., Nat. Rev. Neurosci. 5(5), 2004
PMID: 15100724
Public attitudes toward cognitive enhancement
Fitz N., Nadler R., Manogaran P., Chong E., Reiner P.., 2014
The relationship between Eysenck's personality factors and attitude towards substance use among 13–15-year-olds
Francis L.., 1996
Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons.
Franke AG, Bagusat C, Dietz P, Hoffmann I, Simon P, Ulrich R, Lieb K., BMC Med 11(), 2013
PMID: 23570256
Attitudes toward cognitive enhancement in users and nonusers of stimulants for cognitive enhancement: a pilot study
Franke A., Bonertz C., Christmann M., Engeser S., Lieb K.., 2012
Zur Erhebung der Big-Five-basierten persoenlichkeitsmerkmale im SOEP
Gerlitz J.-Y., Schupp J.., 2005
A theory-based dual-focus alcohol intervention for preadolescents: the Strong African American Families Program.
Gerrard M, Gibbons FX, Brody GH, Murry VM, Cleveland MJ, Wills TA., Psychol Addict Behav 20(2), 2006
PMID: 16784365
Reasoned action and social reaction: willingness and intention as independent predictors of health risk.
Gibbons FX, Gerrard M, Blanton H, Russell DW., J Pers Soc Psychol 74(5), 1998
PMID: 9599437
Cognitive antecedents to adolescent health risk: discriminating between behavioral intention and behavioral willingness
Gibbons F., Gerrard M., Ouellette J., Burzette R.., 1998
Psychopharmacological enhancement
Glannon W.., 2008
Conscience, significant others, and rational choice: extending the deterrence model
Grasmick H., Bursik R.., 1990
Towards responsible use of cognitive-enhancing drugs by the healthy.
Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ., Nature 456(7223), 2008
PMID: 19060880
Short measurements of personality–Validity and reliability of the GSOEP Big Five Inventory (BFI-S)
Hahn E., Gottschling J., Spinath F.., 2012
Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents.
Herman-Stahl MA, Krebs CP, Kroutil LA, Heller DC., J Adolesc Health 39(3), 2006
PMID: 16919799
Relationship between personality change and the onset and course of alcohol dependence in young adulthood.
Hicks BM, Durbin CE, Blonigen DM, Iacono WG, McGue M., Addiction 107(3), 2011
PMID: 21851441

Hoebel J., Kamtsiuris P., Lange C., Müters S., Schilling R., von E.., 2011
Changes in cocaine consumption are associated with fluctuations in self-reported impulsivity and gambling decision-making.
Hulka LM, Vonmoos M, Preller KH, Baumgartner MR, Seifritz E, Gamma A, Quednow BB., Psychol Med 45(14), 2015
PMID: 26081043
Paradigm shift to the integrative big five trait taxonomy
John O., Naumann L., Soto C.., 2008
Falsche Voraussetzungen in der aktuellen Debatte
Kipke R., Heimann H., Wiesing U., Heinz A.., 2010
Five-factor model personality traits in opioid dependence.
Kornor H, Nordvik H., BMC Psychiatry 7(), 2007
PMID: 17683593
Neuroenhancement – Gehirndoping am arbeitsplatz
Kowalski H.., 2013
Differences in Big Five personality traits between alcohol and polydrug abusers: implications for treatment in the therapeutic community
Lackner N., Unterrainer H.-F., Neubauer A.., 2013
Short assessment of the Big Five: robust across survey methods except telephone interviewing.
Lang FR, John D, Ludtke O, Schupp J, Wagner GG., Behav Res Methods 43(2), 2011
PMID: 21424189
Cognitive-enhancing substance use at German universities: frequency, reasons and gender differences.
Mache S, Eickenhorst P, Vitzthum K, Klapp BF, Groneberg DA., Wien Med Wochenschr 162(11-12), 2012
PMID: 22707077
Theory-driven intervention for changing personality: expectancy value theory, behavioral activation, and conscientiousness.
Magidson JF, Roberts BW, Collado-Rodriguez A, Lejuez CW., Dev Psychol 50(5), 2012
PMID: 23106844
Poll results: look who's doping.
Maher B., Nature 452(7188), 2008
PMID: 18401370
The use of prescription drugs and drugs of abuse for neuroenhancement in Europe
Maier L., Schaub M.., 2015
Pharmacological Cognitive Enhancement in Healthy Individuals: A Compensation for Cognitive Deficits or a Question of Personality?
Maier LJ, Wunderli MD, Vonmoos M, Rommelt AT, Baumgartner MR, Seifritz E, Schaub MP, Quednow BB., PLoS ONE 10(6), 2015
PMID: 26107846
Alcohol involvement and the Five-Factor model of personality: a meta-analysis.
Malouff JM, Thorsteinsson EB, Rooke SE, Schutte NS., J Drug Educ 37(3), 2007
PMID: 18047183

Marschall J., Nolting H.-D., Hildebrandt S., Sydow H.., 2015
The five-factor theory of personality
McCrae R., Costa J.., 2008

McLarnon M., Barrett S., Monaghan T., Stewart S.., 2012

Middendorff E., Poskowsky J., Isserstedt W.., 2012
Drugs as instruments: a new framework for non-addictive psychoactive drug use.
Muller CP, Schumann G., Behav Brain Sci 34(6), 2011
PMID: 22074962

Myers I., McCaulley M., Most R.., 1985
Association between nonmedical prescription drug use and health status among young Swiss men.
N'Goran AA, Deline S, Henchoz Y, Baggio S, Studer J, Mohler-Kuo M, Gmel G., J Adolesc Health 55(4), 2014
PMID: 24856409
Neuroenhancement: status quo and perspectives.
Normann C, Berger M., Eur Arch Psychiatry Clin Neurosci 258 Suppl 5(), 2008
PMID: 18985306

Ostendorf F., Angleitner A.., 2004
Habit and intention in everyday life: the multiple processes by which past behavior predicts future behavior
Ouellette J., Wood W.., 1998
Personality and the prediction of consequential outcomes.
Ozer DJ, Benet-Martinez V., Annu Rev Psychol 57(), 2006
PMID: 16318601
Predicting students' intention to use stimulants for academic performance enhancement.
Ponnet K, Wouters E, Walrave M, Heirman W, Van Hal G., Subst Use Misuse 50(3), 2014
PMID: 25438029
Ethics of neuroenhancement: a phantom debate
Quednow B.., 2010
Motives and perceived consequences of nonmedical ADHD medication use by college students: are students treating themselves for attention problems?
Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS., J Atten Disord 13(3), 2008
PMID: 18664714
Predictors of nonmedical ADHD medication use by college students.
Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, Swartzwelder HS., J Atten Disord 13(6), 2009
PMID: 19465730
What should we do about student use of cognitive enhancers? An analysis of current evidence.
Ragan CI, Bard I, Singh I; Independent Scientific Committee on Drugs., Neuropharmacology 64(), 2012
PMID: 22732441
Reliabilität, validität, objektivität
Rammstedt B.., 2010
Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review.
Repantis D, Schlattmann P, Laisney O, Heuser I., Pharmacol. Res. 62(3), 2010
PMID: 20416377
Professor's little helper.
Sahakian B, Morein-Zamir S., Nature 450(7173), 2007
PMID: 18097378
Cognitive enhancement in Germany: prevalence, attitudes, terms, legal status, the ethics debate
Sattler S.., 0
The rationale for consuming cognitive enhancement drugs in university students and teachers.
Sattler S, Sauer C, Mehlkop G, Graeff P., PLoS ONE 8(7), 2013
PMID: 23874778
Attitudes toward pharmacological cognitive enhancement-a review.
Schelle KJ, Faulmuller N, Caviola L, Hewstone M., Front Syst Neurosci 8(), 2014
PMID: 24860438

Schmich P.., 2015
Estimating causal effects with longitudinal data: does unemployment affect mental health?
Schunck R.., 2014
Personality and substance use disorders: a prospective study.
Sher KJ, Bartholow BD, Wood MD., J Consult Clin Psychol 68(5), 2000
PMID: 11068968
The Big Five personality traits and the life course: a 45-year longitudinal study
Soldz S., Vaillant G.., 1999
Ten facet scales for the Big Five Inventory: convergence with NEO PI-R facets, self-peer agreement, and discriminant validity
Soto C., John O.., 2009
What drives adult personality development? A comparison of theoretical perspectives and empirical evidence
Specht J., Bleidorn W., Denissen J., Hennecke M., Hutteman R., Kandler C.., 2014
Misuse of "study drugs:" prevalence, consequences, and implications for policy.
Sussman S, Pentz MA, Spruijt-Metz D, Miller T., Subst Abuse Treat Prev Policy 1(), 2006
PMID: 16764722
Personality change during depression treatment: a placebo-controlled trial.
Tang TZ, DeRubeis RJ, Hollon SD, Amsterdam J, Shelton R, Schalet B., Arch. Gen. Psychiatry 66(12), 2009
PMID: 19996037
Personality plasticity after age 30.
Terracciano A, Costa PT Jr, McCrae RR., Pers Soc Psychol Bull 32(8), 2006
PMID: 16861305
Five-Factor Model personality profiles of drug users.
Terracciano A, Lockenhoff CE, Crum RM, Bienvenu OJ, Costa PT Jr., BMC Psychiatry 8(), 2008
PMID: 18405382
Personality and Substance Use in Midlife: Conscientiousness as a Moderator and the Effects of Trait Change.
Turiano NA, Whiteman SD, Hampson SE, Roberts BW, Mroczek DK., J Res Pers 46(3), 2012
PMID: 22773867

West R.., 2005
Nonmedical prescription stimulant use among a sample of college students: relationship with psychological variables.
Weyandt LL, Janusis G, Wilson KG, Verdi G, Paquin G, Lopes J, Varejao M, Dussault C., J Atten Disord 13(3), 2009
PMID: 19767596
Multiple imputation using chained equations: Issues and guidance for practice.
White IR, Royston P, Wood AM., Stat Med 30(4), 2010
PMID: 21225900
Work-related stress and cognitive enhancement among university teachers.
Wiegel C, Sattler S, Goritz AS, Diewald M., Anxiety Stress Coping 29(1), 2015
PMID: 25747817
Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers.
Winder-Rhodes SE, Chamberlain SR, Idris MI, Robbins TW, Sahakian BJ, Muller U., J. Psychopharmacol. (Oxford) 24(11), 2009
PMID: 19493958
The struggle for meaning and acknowledgement-A psychodynamic view of the phenomenon of neuroenhancement (NE)
Wulf M., Joksimovic L., Tress W.., 2012

AUTHOR UNKNOWN, 1990
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 26779083
PubMed | Europe PMC

Suchen in

Google Scholar